PTSD Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Pregnant women who are receiving prenatal care at the BMC Obstetrics and Gynecology (OB/GYN) Department
- Women who started prenatal care before 28 weeks of pregnancy
- Women who have symptoms of PTSD (post-traumatic stress disorder), either meeting the full diagnosis or having enough symptoms to be close to a diagnosis, as measured by a specific clinical interview tool
Who may not be able to join:
- People whose doctor feels they need a higher level of care, such as a detox program, inpatient hospital stay, or residential treatment, rather than outpatient care
- People who have been diagnosed with psychosis or unstable bipolar disorder, as confirmed through a clinical interview
- People who are already receiving a specific type of PTSD therapy (called exposure-based treatment, such as Written Exposure Therapy, Prolonged Exposure, or Cognitive Processing Therapy) through another provider
- People who are currently incarcerated — those individuals are only able to receive obstetric (pregnancy-related) care at BMC and are not permitted to receive mental health services outside of their correctional facility
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yael I Nillni, PhD, BUSM Department of Psychiatry and VA Boston Healthcare System
Phone: 781-413-6319
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Clinician Administered Scale for PTSD-5 (CAPS-5) at baseline; Clinician Administered Scale for PTSD-5 (CAPS-5) at 8 weeks; Clinician Administered Scale for PTSD-5 (CAPS-5) at 1 month postpartum; Clinician Administered Scale for PTSD-5 (CAPS-5) at 6 months postpartum; Clinician Administered Scale for PTSD-5 (CAPS-5) at 12 months postpartum
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.